Silkworms Are the New Bioreactors? Meet the Startup Quietly Reinventing Biotech
In a world dominated by steel labs and billion-dollar pharma factories, one Indian startup is shaking things up—with bugs. Bengaluru-based Loopworm just raised a jaw-dropping $3.25 million in pre-Series A funding, and their secret weapon? Silkworms.
Yes, you read that right. These humble creatures are at the heart of a biotech revolution, and investors are betting big.
Flip the Script: From Crawlies to Cutting-Edge Proteins
Founded in 2019 by biotech visionaries Ankit Alok Bagaria and Abhi Gawri, Loopworm is building India’s first biomanufacturing platform powered by insects. Forget factories full of steel vats—Loopworm uses silkworms to naturally produce high-value proteins used in vaccines, diagnostics, and animal health.
And now, with $3.25 million in fresh capital from WaterBridge Ventures and Japan’s ENRISSION INDIA CAPITAL, they’re gearing up to go full throttle.
But wait—how does this even work?
The Wild Idea That Could Redefine Medicine
Loopworm isn’t just farming bugs. They’re pioneering a “reactor-free” recombinant protein production platform using genetically enhanced silkworms. That means no expensive bioreactors. No sky-high energy costs. Just pure, high-efficiency protein production, straight from nature.
If they pull this off, they’ll slash the costs of making critical proteins and biologics—opening the doors to cheaper vaccines, faster diagnostics, and more accessible health tech around the world.
Think of it as Tesla meets CRISPR meets nature.
From Aquafeed to Animal Vaccines: The Secret Revenue Engine
While most startups are still testing their tech, Loopworm is already commercial.
They’re producing insect-based proteins and fats for aquaculture (think sustainable fish farming) and pet nutrition, tapping into industries already worth billions. Now, they’re expanding into higher-value segments like animal vaccines and diagnostic tools—all with lower regulatory barriers than human pharma.
That’s a genius strategy: scale where approvals are faster, build momentum, then shoot for the moon.
Why Top Investors Are All-In
The investor list isn’t just impressive—it’s strategic.
- WaterBridge Ventures brings deep SaaS and deep-tech experience
- ENRISSION INDIA CAPITAL opens doors to the Japanese biotech market
- Omnivore, an early backer, is India’s go-to agri-tech VC
These firms know Loopworm isn’t just a startup. It’s a category creator.
And here’s the kicker: Loopworm had already raised $3.4 million in seed capital, bringing total funding to $6.65 million. That’s a lot of firepower for a team working with… well, worms.
The Founders Betting on Bugs
CEO Ankit Alok Bagaria and COO Abhi Gawri aren’t just first-time dreamers. They’re IIT grads and sustainability geeks who saw a way to build profitable biotech in a resource-starved world.
Their mission is bold but clear:
“If it’s not accessible, it’s not medicine.”
And they’re building exactly that: accessible biomanufacturing powered by nature, not machines.
The $290 Billion Opportunity Nobody Saw Coming
Here’s why Loopworm’s timing is perfect:
- The global alternative protein market is on track to hit $290 billion by 2035
- Biomanufacturing bottlenecks are slowing drug innovation
- Climate change is pressuring every industry to cut waste and emissions
Loopworm addresses all three—with bugs.
Forget Silicon Valley software. The next unicorns might just be crawling through sustainable farms in Bengaluru.
What’s Next for Loopworm?
With this new funding, Loopworm is set to:
- Scale commercial production of its silkworm-based protein platform
- Expand to animal health and diagnostic use cases
- Grow partnerships across Japan, Southeast Asia, and Europe
- Hire biotech and product talent to build world-class R&D
They’re not just building a factory. They’re building a future where insects are the engine of clean, affordable biotech.
Final Word: This Is Not Just Another Protein Startup
Loopworm is not trying to make you eat bugs.
They’re using insects to solve some of the biggest challenges in science and health—faster, cleaner, and cheaper. And they might just change the way medicines, diagnostics, and vaccines are made forever.
Keep an eye on this one—because the future of biotech might be crawling quietly under your radar.
